Abstract
A Phase 3, Open-Label, Multicenter Study To Evaluate Eculizumab In Adolescents With Refractory Generalized Myasthenia Gravis (S5.009)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1212/wnl.0000000000202200
Copy DOIJournal: Neurology | Publication Date: Apr 25, 2023 |
Citations: 2 |
A Phase 3, Open-Label, Multicenter Study To Evaluate Eculizumab In Adolescents With Refractory Generalized Myasthenia Gravis (S5.009)
Join us for a 30 min session where you can share your feedback and ask us any queries you have